Ticagrelor Clinical Trials

5 actively recruiting trials

▲ +1 trial since May 2026

Also known as: Brilinta/Brilique, Brilique

Pipeline

Phase 3: 2Phase 4: 2

Top Sponsors

Shanghai Zhongshan Hospital1
Radboud University Medical Center1
Fu Wai Hospital, Beijing, China1
Cardiocentro Ticino1
Campus Bio-Medico University1

Indications

Heart Disease5
Coronary Artery Disease3
Coagulation Factors1
Antiplatelet Therapy1
Antiplatelet Drugs1

Other5 trials

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Phase 4

SAPT Versus DAPT in Incomplete Revascularization After CABG

Phase 3

Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

N/A

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Phase 3

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.